Strengthening the Clinical Trial Ecosystem in Indonesia: Equilab International and UGM Academic Hospital Signed First Clinical Study Agreement

On February 10, 2026, Equilab International and UGM Academic Hospital or also known as Rumah Sakit Akademik Universitas Gadjah Mada (RSA UGM) signed a clinical trial agreement to strengthen clinical trial projects in Indonesia. The agreement was signed by Ronal Simanjuntak, President Director of Equilab International, and Dr. dr. Darwito, S.H., Sp.B(K)On, Director of RSA UGM. This partnership is designed to combine academic clinical excellence with professional study management, ensuring that research is conducted with high scientific rigor and operational efficiency.

Equilab International, an established Indonesian CRO with over 22 years of experience, provides the management expertise required to bring clinical research in Indonesia to the global stage. This collaboration focuses on optimizing site operations, patient recruitment strategies, and data quality. By integrating RSA UGM’s clinical infrastructure with Equilab’s experience in study execution, the partnership creates a clear pathway for sponsors seeking to their clinical programs into Yogyakarta, a one of medical and academic hub in Indonesia.

During the ceremony, the leadership of both organizations discussed the long-term value of this initiative. Dr. dr. Darwito stated, “This collaboration with Equilab International allows RSA UGM to maximize our academic and clinical resources, ensuring our hospital remains at the forefront of medical innovation through high-quality clinical trials.” Ronal Simanjuntak added, “Partnering with a prestigious academic institution like RSA UGM is a vital step in our mission to elevate Indonesia’s clinical research profile. We are dedicated to providing sponsors with the specialized expertise and infrastructure required for successful study outcomes.”

Ultimately, this collaboration underscores a broader objective for the national research infrastructure. Through sustained partnerships with established institutions such as RSA UGM, Equilab International remains dedicated to strengthening Indonesia’s competitive standing in global clinical research, particularly regarding the development of innovative pharmaceutical drugs. This initiative not only enhances site readiness but also ensures that the clinical trial ecosystem in Indonesia continues to be known globally.